Last reviewed · How we verify

MK0954, /Duration of Treatment : 5 Years

Organon and Co · Phase 3 active Small molecule

MK0954, /Duration of Treatment : 5 Years is a Neurokinin-1 (NK1) receptor antagonist Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).

MK0954 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.

MK0954 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).

At a glance

Generic nameMK0954, /Duration of Treatment : 5 Years
SponsorOrganon and Co
Drug classNeurokinin-1 (NK1) receptor antagonist
TargetNK1 receptor
ModalitySmall molecule
Therapeutic areaOncology; Pain Management
PhasePhase 3

Mechanism of action

The drug works by binding to and blocking NK1 receptors, which are involved in pain transmission and emetic (nausea/vomiting) pathways. By antagonizing these receptors, MK0954 may reduce pain perception and chemotherapy-induced nausea and vomiting (CINV). This mechanism targets both the peripheral and central nervous system effects mediated by substance P.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MK0954, /Duration of Treatment : 5 Years

What is MK0954, /Duration of Treatment : 5 Years?

MK0954, /Duration of Treatment : 5 Years is a Neurokinin-1 (NK1) receptor antagonist drug developed by Organon and Co, indicated for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).

How does MK0954, /Duration of Treatment : 5 Years work?

MK0954 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.

What is MK0954, /Duration of Treatment : 5 Years used for?

MK0954, /Duration of Treatment : 5 Years is indicated for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).

Who makes MK0954, /Duration of Treatment : 5 Years?

MK0954, /Duration of Treatment : 5 Years is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What drug class is MK0954, /Duration of Treatment : 5 Years in?

MK0954, /Duration of Treatment : 5 Years belongs to the Neurokinin-1 (NK1) receptor antagonist class. See all Neurokinin-1 (NK1) receptor antagonist drugs at /class/neurokinin-1-nk1-receptor-antagonist.

What development phase is MK0954, /Duration of Treatment : 5 Years in?

MK0954, /Duration of Treatment : 5 Years is in Phase 3.

What are the side effects of MK0954, /Duration of Treatment : 5 Years?

Common side effects of MK0954, /Duration of Treatment : 5 Years include Headache, Dizziness, Fatigue, Constipation.

What does MK0954, /Duration of Treatment : 5 Years target?

MK0954, /Duration of Treatment : 5 Years targets NK1 receptor and is a Neurokinin-1 (NK1) receptor antagonist.

Related